A carregar...
Severe Delayed-Onset Neutropenia Induced by Ocrelizumab
BACKGROUND: Ocrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS). The adverse event profile is still being determined through postmarketing surveillance and case reports. OBJECTIVE: To report a case of sev...
Na minha lista:
| Publicado no: | Neurohospitalist |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8022193/ https://ncbi.nlm.nih.gov/pubmed/33868559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1941874420936438 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|